Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan)

被引：2
|
作者：
Petramala, Luigi [1 ]
Letizia, Claudio [1 ]
机构：
[1] Sapienza Univ Rome, Policlin Umberto 1, Unit Secondary Arterial Hypertens, Dept Translat & Precis Med, Viale Policlin 155, I-00185 Rome, Italy
来源：
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY | 2020年 / 6卷 / 04期
关键词：
D O I：
10.1093/ehjcvp/pvaa035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：252 / 252
页数：1
相关论文
共 50 条
  • [21] ACE inhibitor-angiotensin receptor blocker combinations: A clinician's perspective
    Doulton, TWR
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2006, 6 (05) : 491 - 497
  • [22] Angiotensin II Receptor Blocker Neprilysin Inhibitor (ARNI): New Avenues in Cardiovascular Therapy
    Volpe M.
    Tocci G.
    Battistoni A.
    Rubattu S.
    High Blood Pressure & Cardiovascular Prevention, 2015, 22 (3) : 241 - 246
  • [23] Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure
    Fala, Loretta
    AMERICAN HEALTH AND DRUG BENEFITS, 2015, 8 (06):
  • [24] Dose-response efficacy of valsartan, a new angiotensin II receptor blocker
    Pool, JL
    Glazer, R
    Chiang, YT
    Gatlin, M
    JOURNAL OF HUMAN HYPERTENSION, 1999, 13 (04) : 275 - 281
  • [25] Dose-response efficacy of valsartan, a new angiotensin II receptor blocker
    JL Pool
    R Glazer
    Y-T Chiang
    M Gatlin
    Journal of Human Hypertension, 1999, 13 : 275 - 281
  • [26] Effect of food on the oral bioavailability of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
    Ayalasomayajula, Surya
    Langenickel, Thomas H.
    Chandra, Priya
    Wolfson, Edward D.
    Albrecht, Diego
    Zhou, Wel
    Pal, Parasar
    Rajman, Iris
    Sunkara, Gangadhar
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (12) : 1012 - 1018
  • [27] The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond
    Kazuomi Kario
    Current Cardiology Reports, 2018, 20
  • [28] Protective effect of valsartan alone and in combination with neprilysin inhibitor (valsartan plus sacubitril) against hepatic ischemia-reperfusion injury: targeting angiotensin II receptor-neprilysin and modulating SMAD-4/NF-κβ/JNK pathways in rats
    Abouzed, Deiaa E. Elsayed
    Bafail, Duaa Abdullah
    Refaie, Shereen Mahmoud
    Aboelez, Moustafa O.
    Elsayed, Asmaa A.
    Mallasiy, L. O.
    Bayoumy, Nervana M. K.
    Hagar, Hanan
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,
  • [29] The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey
    Schoenfeld, Heidi A.
    West, Tim
    Verghese, Philip B.
    Holubasch, Mary
    Shenoy, Neeta
    Kagan, David
    Buono, Chiara
    Zhou, Wei
    DeCristofaro, Marc
    Douville, Julie
    Goodrich, Geoffrey G.
    Mansfield, Keith
    Saravanan, Chandra
    Cumin, Frederic
    Webb, Randy L.
    Bateman, Randall J.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 323 : 53 - 65
  • [30] The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond
    Kario, Kazuomi
    CURRENT CARDIOLOGY REPORTS, 2018, 20 (01)
12345